Intellia Therapeutics Inc is trading at $13.20 (-10.51%) as investors lock in gains following a recent rally, while broader market pressure and cash-burn risks weigh on the stock.
- The stock saw a sharp reversal from its June 04, 2026, close of $14.75, retracing much of its prior 13.29% surge.
- Speculative biotech names are under pressure as the Nasdaq and other growth-oriented sectors face broader market weakness.
- Investor focus has shifted back to the company's capital requirements and potential dilution risks.